{"version":"1.0","provider_name":"Avalere Health Advisory","provider_url":"https:\/\/advisory.avalerehealth.com","title":"FDA and Sponsors Discuss Quality Challenges in the Breakthrough Therapy Pathway","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"UE1dvcHx6f\"><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/fda-and-sponsors-discuss-quality-challenges-in-the-breakthrough-therapy-pathway\">FDA and Sponsors Discuss Quality Challenges in the Breakthrough Therapy Pathway<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/advisory.avalerehealth.com\/insights\/fda-and-sponsors-discuss-quality-challenges-in-the-breakthrough-therapy-pathway\/embed#?secret=UE1dvcHx6f\" width=\"600\" height=\"338\" title=\"&#8220;FDA and Sponsors Discuss Quality Challenges in the Breakthrough Therapy Pathway&#8221; &#8212; Avalere Health Advisory\" data-secret=\"UE1dvcHx6f\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2018\/08\/Insight_6.20.2018_Real-World-Evidence_Is-it-a-Game-Changer-for-the-FDA_570x388.jpg","thumbnail_width":570,"thumbnail_height":388,"description":"The meeting featured case studies from the biopharmaceutical industry regarding expedited development of drugs and biologics, as well as panel discussions comprised of members from both the Food and Drug Administration (FDA) and sponsors. Meeting Highlights.\u00a0Panelists highlighted the overwhelming success of the breakthrough therapy designation (BTD) program in delivering treatments to patients with unmet medical&hellip;"}